Terms: = Thyroid cancer AND PML, TRIM19, 5371, ENSG00000140464, MYL, PP8675, RNF71
13 results:
1. Single-cell combined with bulk-RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine.
Zhang W; Yu Y; Yang F
Environ Toxicol; 2024 Feb; 39(2):695-707. PubMed ID: 37647361
[TBL] [Abstract] [Full Text] [Related]
2. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.
Liu J; Wang Y; Tian Z; Lin Y; Li H; Zhu Z; Liu Q; Su S; Zeng Y; Jia W; Yang Y; Xu S; Yao H; Jiang W; Song E
Nat Commun; 2022 May; 13(1):3011. PubMed ID: 35641481
[TBL] [Abstract] [Full Text] [Related]
3. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
4. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for pml/RARA-induced immortalization.
Zhou J; Pérès L; Honoré N; Nasr R; Zhu J; de Thé H
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9238-43. PubMed ID: 16757557
[TBL] [Abstract] [Full Text] [Related]
5. The aryl hydrocarbon receptor activates the retinoic acid receptoralpha through SMRT antagonism.
Widerak M; Ghoneim C; Dumontier MF; Quesne M; Corvol MT; Savouret JF
Biochimie; 2006; 88(3-4):387-97. PubMed ID: 16480812
[TBL] [Abstract] [Full Text] [Related]
6. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract] [Full Text] [Related]
7. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract] [Full Text] [Related]
8. Loss of the tumor suppressor pml in human cancers of multiple histologic origins.
Gurrieri C; Capodieci P; Bernardi R; Scaglioni PP; Nafa K; Rush LJ; Verbel DA; Cordon-Cardo C; Pandolfi PP
J Natl Cancer Inst; 2004 Feb; 96(4):269-79. PubMed ID: 14970276
[TBL] [Abstract] [Full Text] [Related]
9. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.
Puccetti E; Obradovic D; Beissert T; Bianchini A; Washburn B; Chiaradonna F; Boehrer S; Hoelzer D; Ottmann OG; Pelicci PG; Nervi C; Ruthardt M
Cancer Res; 2002 Dec; 62(23):7050-8. PubMed ID: 12460926
[TBL] [Abstract] [Full Text] [Related]
10. Expression of promyelocytic leukaemia protein in thyroid neoplasms.
Yu E; Lee KW; Lee HJ
Histopathology; 2000 Oct; 37(4):302-8. PubMed ID: 11012736
[TBL] [Abstract] [Full Text] [Related]
11. Heterogeneous nuclear expression of the promyelocytic leukemia (pml) protein in normal and neoplastic human tissues.
Gambacorta M; Flenghi L; Fagioli M; Pileri S; Leoncini L; Bigerna B; Pacini R; Tanci LN; Pasqualucci L; Ascani S; Mencarelli A; Liso A; Pelicci PG; Falini B
Am J Pathol; 1996 Dec; 149(6):2023-35. PubMed ID: 8952536
[TBL] [Abstract] [Full Text] [Related]
12. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation.
Labelle Y; Zucman J; Stenman G; Kindblom LG; Knight J; Turc-Carel C; Dockhorn-Dworniczak B; Mandahl N; Desmaze C; Peter M
Hum Mol Genet; 1995 Dec; 4(12):2219-26. PubMed ID: 8634690
[TBL] [Abstract] [Full Text] [Related]
13. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia.
De Luca LM
FASEB J; 1991 Nov; 5(14):2924-33. PubMed ID: 1661245
[TBL] [Abstract] [Full Text] [Related]
